Please assess the completion status of the following clinical trial:

Trial Title: BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CD4 Count \>50~* Viral load 200-75,000 on two most recent measures~* More than 16 weeks on standard dose Kaletra (LPV/r)~* May be initial PI regimen or prior PI usage~* Up to 50-fold resistance to LPV/r~Exclusion Criteria:~* Age \< 18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).